Citable filing context

SYK filing events and research context

Server-rendered

SYK's research view summarizes recent SEC filing context, starting with management_change from May 20, 2026.

SYK filing events and research context
FiledItemContext
May 20, 2026management_changeWilliam E. Berry, Jr. retires as CAO; Emily Baculik appointed Chief Accounting Officer effective September 1, 2026.
May 8, 2026management_changeShareholders elected ten directors, ratified auditors, and approved executive compensation at the annual meeting.
Apr 30, 2026earningsStryker reported Q1 2026 net sales of $6.0 billion (up 2.6%) and reported EPS of $1.93 (up 14.2%).
Apr 30, 2026Guidance: adjusted_net_earnings_per_diluted_share14.90 to 15.10
Apr 30, 2026Guidance: organic_net_sales_growth8.00 to 9.50
Oct 30, 2025Guidance: adjusted_eps_diluted13.50 to 13.60
May 11, 2026mda_quarterlyStryker reported first-quarter 2026 net sales growth of 2.6%, or 1.0% in constant currency, with organic sales increasing 2.1% from higher unit volume and pricing. Adjusted operating income margin contracted 180 basis points to 21.1%, and adjusted diluted EPS decreased 8.5% to $2.60. A significant cybersecurity incident caused operational disruptions, leading to higher manufacturing and supply chain costs and idle production time, which negatively impacted gross profit margin (63.3%) and operating income across both segments. MedSurg and Neurotechnology sales grew 5.0% (3.6% constant currency), driven by strong performance in Vascular (up 27.5%) and Instruments. Orthopaedics sales were flat (down 1.8% constant currency), but organic sales increased 4.1% from higher unit volumes across Knees, Hips, and Trauma & Extremities. The company reorganized, forming a new Ortho Tech business by combining orthopaedic instruments with Mako and other enabling technologies to enhance innovation. Macroeconomic risks include new tariffs, slower economic growth, and inflation. Cash flow from operations improved significantly to $581 million.
Feb 11, 2026businessStryker Corporation is a global leader in medical technologies, primarily operating through two segments: MedSurg and Neurotechnology, which generated 62% of 2025 net sales, and Orthopaedics, contributing 38%. The MedSurg and Neurotechnology segment encompasses surgical equipment, navigation systems, endoscopic and communication systems, patient handling, emergency medical equipment, AI-assisted virtual care platforms, and minimally invasive products for stroke and venous thromboembolism (Vascular), significantly expanded by the Inari acquisition. Recent product launches include the Steri-Shield 8 PPE, LIFEPAK 35 monitor/defibrillator, and the Broadway System for stroke. The Orthopaedics segment focuses on implants for joint replacements (hip, knee, shoulder, ankle) and trauma surgeries. A key competitive advantage is the Mako robotic-arm assisted technology, with over two million procedures performed, and recent advancements like the Mako 4 platform, Q-Guidance system, and new Mako Total Hip and Mako Shoulder applications. Stryker competes globally with major players such as Zimmer, Medtronic, and Johnson & Johnson MedTech, selling products in approximately 61 countries. The company navigates a complex regulatory environment, including FDA and EU MDR, and faces ongoing healthcare cost containment pressures.

Source: SEC EDGAR filing text and events; period May 20, 2026; filed May 20, 2026.

Continue research

Keep researching SYK

Follow same-sector companies and source explainers connected to the research view.

Browse Health Care

Related tickers

LLY
Lilly (Eli)
$1.02T
Health Care
Open company page →
JNJ
Johnson & Johnson
$558.88B
Health Care
Open company page →
ABBV
AbbVie
$393.91B
Health Care
Open company page →
UNH
UnitedHealth Group
$369.32B
Health Care
Open company page →
MRK
Merck & Co.
$295.00B
Health Care
Open company page →
AZN
ASTRAZENECA PLC
$281.75B
Health Care
Open company page →

Related explainers

Understanding 8-K filings

A factual guide to SEC Form 8-K current reports and the material company events they can disclose between quarterly filings.

Read explainer →
Reading a 10-Q

A factual guide to quarterly SEC Form 10-Q reports, how they differ from annual 10-K filings, and what readers can inspect first.

Read explainer →
S-1 and the IPO prospectus

A factual guide to Form S-1 registration statements and the disclosures companies provide before a public offering.

Read explainer →
Reading an SEC 10-K

A factual guide to the core 10-K sections investors use for company context: business description, risk factors, MD&A, financial statements, and segment disclosures.

Read explainer →